Who owns Relmada Therapeutics Inc?
- Ticker: RLMD
- CUSIP Number: 75955j402
Tip: Access positions for across all investors
Analyze quarterly positions in Relmada Therapeutics with up to 7 years of data, all consolidated into one spreadsheet
Download as csv
Download as Excel
Top investors of Relmada Therapeutics stock
Who bought or sold Relmada Therapeutics Inc this quarter?
| Fund or Company Name | Shares Held | Valued At | Change in Shares | As Of | Actions |
|---|---|---|---|---|---|
| Ikarian Capital | 1.8M | $3.7M | 4477% | Sep 2025 |
|
| Driehaus Capital Management | 740k | $1.5M | 0% | Sep 2025 |
|
| Boothbay Fund Management | 693k | $1.4M | 100% | Sep 2025 |
|
| Acadian Asset Management | 583k | $1.2M | -6% | Sep 2025 |
|
| BlackRock | 508k | $1.0M | 0% | Sep 2025 |
|
| Vanguard Group | 419k | $841k | 15% | Sep 2025 |
|
| AdvisorShares Investments | 404k | $811k | 2% | Sep 2025 |
|
| Geode Capital Management | 296k | $596k | -2% | Sep 2025 |
|
| Marshall Wace | 272k | $547k | 76% | Sep 2025 |
|
| Deutsche Bank Aktiengesellschaft | 225k | $452k | 0% | Sep 2025 |
|
| CI Private Wealth | 207k | $402k | 0% | Sep 2025 |
|
| Susquehanna International | 204k | $411k | 211% | Sep 2025 |
|
| Two Sigma Investments | 174k | $349k | 82% | Sep 2025 |
|
| Renaissance Technologies | 170k | $341k | 13% | Sep 2025 |
|
| Parsons Capital Management | 163k | $328k | 0% | Sep 2025 |
|
| Rbf Capital | 163k | $328k | 0% | Sep 2025 |
|
| State Street Corporation | 102k | $205k | -5% | Sep 2025 |
|
| We Are One Seven | 100k | $201k | 0% | Sep 2025 |
|
| Jane Street | 86k | $172k | -25% | Sep 2025 |
|
| UBS Group | 60k | $120k | -67% | Sep 2025 |
|
| Northern Trust | 59k | $119k | -1% | Sep 2025 |
|
| LMR Partners | 56k | $112k | 1% | Sep 2025 |
|
| Simplex Trading | 53k | $106k | 2087% | Sep 2025 |
|
| apricus wealth | 48k | $95k | 0% | Sep 2025 |
|
| Two Sigma Advisers | 39k | $78k | 55% | Sep 2025 |
|
| AlTi Global | 32k | $64k | 0% | Sep 2025 |
|
| Robertson Stephens Wealth Management | 25k | $50k | 0% | Sep 2025 |
|
| Pandora Wealth | 20k | $40k | 0% | Sep 2025 |
|
| Citadel Advisors | 18k | $37k | 100% | Sep 2025 |
|
| Tortoise Investment Management | 14k | $28k | -36% | Sep 2025 |
|
| Lido Advisors | 14k | $28k | 0% | Sep 2025 |
|
| Pensionmark Financial Group | 11k | $21k | -51% | Sep 2025 |
|
| Bedel Financial Consulting | 10k | $20k | 0% | Sep 2025 |
|
| Barclays | 10k | $20k | 999900% | Sep 2025 |
|
| American Capital Advisory | 2.0k | $3.9k | 0% | Sep 2025 |
|
| Tower Research Capital | 1.6k | $3.2k | -74% | Sep 2025 |
|
| Morgan Stanley | 852.00 | $511.200000 | 100% | Jun 2025 |
|
| Farther Finance Advisors | 838.00 | $1.7k | 100% | Sep 2025 |
|
| SBI Securities | 102.00 | $204.999600 | 0% | Sep 2025 |
|
| Bnp Paribas Arbitrage, Snc | 93.00 | $187.004400 | 7% | Sep 2025 |
|
| Advisor Group Holdings | 5.00 | $9.000000 | 0% | Sep 2025 |
|
| Front Row Advisors | 2.00 | $4.000000 | -33% | Sep 2025 |
|
| Royal Bank of Canada | 1.00 | $0 | 0% | Sep 2025 |
|
Who sold out of Relmada Therapeutics?
| Fund or Company Name | Date Sold | Shares Held | Valued At |
|---|---|---|---|
| ADAR1 Capital Management | Jun 2025 | 130k | $78k |
| Goldman Sachs Group | Mar 2025 | 121k | $33k |
| XTX Topco | Jun 2025 | 46k | $28k |
| Wealthedge Investment Advisors | Jun 2025 | 28k | $17k |
| Group One Trading | Jun 2025 | 26k | $16k |
| Ground Swell Capital | Jun 2025 | 15k | $9.2k |
| Hrt Financial | Jun 2025 | 12k | $7.0k |
| Raymond James Financial | Jun 2025 | 587.00 | $352.023900 |
| Jpmorgan Chase & Co | Mar 2025 | 158.00 | $43.007600 |